Drugs / TTX-MC138
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06260774 | Sep 2024 → Sep 2025 overdue | — | TransCode Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTX-MC138 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06260774 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion on Day 1” NCT06260774 ↗ |